Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company’s post-earnings decline, as he remarked: What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let’s just say it was brutal. They’re talking about a 5% to 13% sales hit this year, thanks to pricing pressures amid fierce competition for the GLP-1 business. It s ...